Till nowadays, although many novel thrombolysis drugs have emerged for ischemic stroke treatment (e.g. Tenecteplase), recombinant tissue plasminogen activator (r-tPA) treatment within a narrow therapeutic time window (within 4.5 hours from stroke onset) is still the only FDA-approved thrombolysis agent for ischemic stroke patients 2, 3. This evidence concerns the gene PLAT and stroke disorder.